Table 2.
International COPD Genetics Consortium study populations—Phenotypes
| Spirometry |
Chest CT |
Other Phenotypes |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Age Range | Gender (% Male) | Minimum Pack-Years | Pre-BD | Post-BD | Obtained? | Visual Assessment | Quantitative Assessment | Exac** | Co-Mor** | Lung Function Decline |
| ANOLD | 40-91 | 94 | 10 | Yes | Yes | No | - | - | Yes | Yes | No |
| COPACETIC | 50-80 | 98 | 20 | Yes | Some | Yes | No | Yes | Yes | No | Yes |
| COPDGene | 45-80 | 52 | 10 | Yes | Yes | Yes | No | Yes | Yes | Yes | No |
| COSYCONET | >40 | n/a | 0 | Yes | Yes | Some | Yes | Yes | Yes | Yes | Yes |
| ECLIPSE | 40-75 | 66 | 10 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| EU COPD/East Midlands Consortium | Mean 66 | 70 | 10 | Yes | Yes | No | - | - | No | Yes | Some |
| EvA | 45-75 | 65 | 5 | Yes | Yes | Yes | No | Yes | No | Yes | No |
| GenKOLS | 40-81 | 66 | 2.5 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Some |
| Hokkaido | 41-87 | 94 | 12 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| ICE COLD | Mean 66 | 57 | 0 | No | Yes | No | - | - | Yes | Yes | Yes |
| KOLD | 45-82 | 92 | 10 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Leuven | 43-90 | 75 | 15 | Yes | Yes | Yes | Yes | No | Yes | Yes | No |
| Lung Health Study | 35-60 | 63 | 10 | Yes | Yes | No | - | - | Yes | Some | Yes |
| New Zealand | 40-85 | 60 | 15 | Yes | No | No | - | - | No | Yes | No |
| NETT | Mean 67 | 73 | 0 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
| PAC COPD | Mean 68; Range 44-86 | 93 | 0 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| SPIROMICS | TBD | TBD | TBD | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Transcontinental: Korea | 40-80 | 97 | 10 | Yes | Yes | No | Yes | Yes | No | ||
| Transcontinental: Poland | 40-80 | 69 | 10 | Yes | Yes | No | Yes | Yes | No | ||
| Wake Forest | 42-88 | 96 | 20 | Yes | No | No | - | - | No | Yes | Yes |
| ARIC | 45-64 | 45 | 0 | Yes | No | No | - | - | Yes | Yes | Yes |
| Cardiovascular Health Study | 65-95 | 43 | 0 | Yes | No | No | No | Yes | Yes | ||
| Cleveland Family Study | 23-88 | 48 | 0 | Yes | No | No | - | - | No | Yes | No |
| Copenhagen City Heart | n/a | n/a | 0 | Yes | n/a | No | - | - | Yes | Yes | n/a |
| Copenhagen General Population | n/a | n/a | 0 | Yes | n/a | No | - | - | Yes | Yes | ? |
| CARDIA | 27-44 | 45 | 0 | Yes | No | No | - | - | No | Yes | Yes |
| EMCAP | >60 | 50 | 10 | Yes | Some | Yes | Yes | Yes | Yes | Yes | Yes |
| Framingham | 19-92 | 46 | 0 | Yes | Some | In Subset | Pending | Pending | No | Yes | Yes |
| Jackson Heart Study | 21-93 | 38 | 0 | Yes | No | No | - | - | No | Yes | No |
| Lifelines | 21-88 | 41 | 0 | Yes | No | No | - | - | No | Yes | No |
| Lovelace Smokers Cohort | 40-75 | 22 | 15 | Yes | Yes | No | - | - | Yes | Yes | Yes |
| MESA Lung | 45-84 | 49 | 0 | Yes | sPe | Yes | Pending | Yes | Yes | Yes | Pending |
| MESA Lung SHARe | 45-84 | 50 | 0 | No | No | Yes (cardiac) | No | Yes | No | Yes | No |
| Normative Aging Study | 21->80 | 100 | 0 | Yes | No | No | - | - | No | Yes | Yes |
| Rotterdam Study | >45 | 45 | 0 | Yes | No | No | - | - | No | Yes | Pending (RS1) |
| SpiroMeta | 8-93* | 42* | 0 | Yes | In a subset | No | - | - | No | No | No |
| Vlagtwedde/Vlaardingen | 35-79 | 51 | 0 | Yes | No | No | - | - | No | Some | Yes |
| Boston Early-Onset COPD | >10 | 42 | 0 | Yes | Yes | No | - | - | Yes | Yes | No |
| International COPD Genetics Network | 45-65 | 46 | 5 | Yes | Yes | In Subset | Yes | Yes | Yes | Yes | No |
*
For a subset of individuals (n = 20, 288) with information on age and gender currently available.
**
Abbreviations: “Exac“ = Data available regarding COPD exacerbations; “CoMor“ = Data available regarding co-morbid diseases.